FDA Inspection 1266744 — Hubei Enoray Biopharmaceutical Co., Ltd.
The FDA completed an inspection of Hubei Enoray Biopharmaceutical Co., Ltd. on March 13, 2025 in Huanggang. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 13, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Huanggang (China)